Entresto

News

Novartis' new drugs outweigh Entresto decline in Q3

Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.

News

Novartis sheds staff as Entresto patent expiry looms

Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto.

News

Novartis bid to block generic Entresto in US suffers setback

An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.

News

Judge rebuffs Novartis bid to block generic Entresto

A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto.

News

Novartis will appeal Entresto patent setback

Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t

News

Novartis cuts 10% of R&D projects in ‘focused’ strategy

Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat

Novartis' new drugs outweigh Entresto decline in Q3

Novartis sheds staff as Entresto patent expiry looms

Novartis bid to block generic Entresto in US suffers setback

Judge rebuffs Novartis bid to block generic Entresto

Novartis will appeal Entresto patent setback

Novartis cuts 10% of R&D projects in ‘focused’ strategy

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Entresto

Editor's Picks